Bicara Therapeutics· @BicaraTx · X·· 4 天前评分45
正文 · 原文
We’ll be at #ESMO2026 this week!
HPV-negative head and neck squamous cell carcinoma (#HNSCC) is a distinct and clinically challenging subset of the disease, representing the vast majority of HNSCC
cases in the recurrent/metastatic setting.
Visit Booth #8012 to learn about our research and clinical development in HPV-negative HNSCC, or visit http://bicara.com.
83 浏览 · 0 赞 · 1 转发 · 0 回复
会议摘要
NCT06295731NCT06295731按 - **标题 / Title：** INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC 对上
- **标题 / Title：** INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
https://esmocongress.esmo.org来源：Bicara Therapeutics · x.com